HIV Drug Pay-For-Delay Claims Too Speculative, Gilead Says
By Bryan Koenig · October 21, 2022, 6:50 PM EDT
Gilead Sciences Inc. wants a California federal court to toss a proposed class action accusing the pharmaceutical company of paying off would-be generic competitors to its HIV drugs to delay market...
To view the full article, register now.